Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Leonard M. Klein"'
Autor:
Thomas A. Rado, Danjie Zhang, Wen Shi, Derek Nay, Andrei R. Shustov, Thomas A. Giever, Leonard M. Klein, Alfred Saleh, Jeffrey P. Sharman, Kathryn S. Kolibaba, Andres Forero, Sarit Assouline
Publikováno v:
Blood. 128:2963-2963
Introduction: Entospletinib (GS-9973) is an orally bioavailable, selective inhibitor of spleen tyrosine kinase (Syk). Syk is a mediator of B-cell receptor signaling in normal and transformed B-cells. Targeting the B-cell receptor (BCR)-signaling path
Autor:
Kathryn S. Kolibaba, Jing He, Jeff P. Sharman, Jing Hu, Michael Boxer, Steve Abella, Christopher A. Yasenchak, Leonard M. Klein, Clarence Eng
Publikováno v:
Blood. 126:1545-1545
Background: Spleen tyrosine kinase (Syk) is a mediator of B-cell receptor signaling in normal and transformed B-cells. Entospletinib is an orally bioavailable, selective inhibitor of Syk. Methods: This Phase 2 trial is evaluating entospletinib 800 mg
Autor:
Jing Hu, Christopher A. Yasenchak, Leonard M. Klein, Anita Reddy, Jing He, Jeff P. Sharman, Julie A. Di Paolo, Steve Abella, Clarence Eng, Michael Boxer, Kathryn S. Kolibaba
Publikováno v:
Blood. 126:4152-4152
Background: Spleen tyrosine kinase (Syk) is a mediator of B-cell receptor signaling in normal and transformed B-cells. GS-9973 is an orally bioavailable, selective inhibitor of Syk. Methods: This Phase 2 trial enrolled 41 patients with CLL and 15 pat
Autor:
Kathryn S. Kolibaba, Jeff P. Sharman, Christopher A. Yasenchak, Michael J. Hawkins, Steve Abella, Meihua Wu, Leonard M. Klein, Michael Boxer
Publikováno v:
Blood. 124:4419-4419
Background: Spleen tyrosine kinase (Syk) is a mediator of B-cell receptor signaling in normal and transformed B-cells. Entospletinib is an orally bioavailable, selective inhibitor of Syk (Kd 7.6 nM, no other kinase < 100 nM). Methods: This Phase 2 tr
Autor:
Michael Boxer, Kathryn S. Kolibaba, Christopher A. Yasenchak, Jing Hu, Jeff P. Sharman, Anita Reddy, Michael J. Hawkins, Feng Jin, Leonard M. Klein, Flordeliza Melchor-Khan, Julie Di Paolo
Publikováno v:
Blood. 122:1634-1634
Title Phase 2 Trial of GS-9973, a selective Syk inhibitor, has Activity in Subjects with Chronic Lymphocytic Leukemia (CLL) Introduction Spleen tyrosine kinase (Syk) is an essential mediator of B-cell receptor signaling in normal and transformed B-ce